Begonia kimlongii (B. sect. Petermannia, Begoniaceae), a new species from Dak Lak, Central Highlands, Vietnam

Nguyen, Van Canh; HOANG, THANH SON; Lin, Che-Wei; Nguyen, Van Khuong

doi:10.11646/phytotaxa.547.2.7

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, there have been various studies on the investigation, identification, and listing of plant species in the Central Highlands and of medicinal plants used by the ethnic minorities living in Dak Lak and conservation studies. However, very few studies have been conducted on screening bioactivities, purification, and identification of chemical structures of bioactive compounds from these diverse medicinal plants for the development of drugs or functional foods [ 12 , 13 , 14 ]. This study aimed to screen, purify, and identify chemical structures of aGIs from medicinal plants used by the E De ethnic tribe for the potential management of T2D.…”

Section: Introductionmentioning

confidence: 99%

Screening and Elucidation of Chemical Structures of Novel Mammalian α-Glucosidase Inhibitors Targeting Anti-Diabetes Drug from Herbals Used by E De Ethnic Tribe in Vietnam

et al. 2023

View full text Add to dashboard Cite

Among ten extracts of indigenous medicinal plants, the MeOH extract of Terminalia triptera Stapf. (TTS) showed the most efficient mammalian α-glucosidase inhibition for the first time. The data of screening bioactive parts used indicated that the TTS trunk bark and leaves extracts demonstrated comparable and higher effects compared to acarbose, a commercial anti-diabetic drug, with half-maximal inhibitory concentration (IC50) values of 181, 331, and 309 µg/mL, respectively. Further bioassay-guided purification led to the isolation of three active compounds from the TTS trunk bark extract and identified as (−)-epicatechin (1), eschweilenol C (2), and gallic acid (3). Of these, compounds 1 and 2 were determined as novel and potent mammalian α-glucosidase inhibitors. The virtual study indicated that these compounds bind to α-glucosidase (Q6P7A9) with acceptable RMSD values (1.16–1.56 Å) and good binding energy (DS values in the range of −11.4 to −12.8 kcal/mol) by interacting with various prominent amino acids to generate five and six linkages, respectively. The data of Lipinski’s rule of five and absorption, distribution, metabolism, excretion and toxicity (ADMET)-based pharmacokinetics and pharmacology revealed that these purified compounds possess anti-diabetic drug properties, and the compounds are almost not toxic for human use. Thus, the findings of this work suggested that (−)-epicatechin and eschweilenol C are novel potential mammalian α-glucosidase inhibitor candidates for type 2 diabetes treatment.

show abstract

Section: Introductionmentioning

confidence: 99%